Antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis / 中华肝脏病杂志
Chinese Journal of Hepatology
;
(12): 109-112, 2010.
Artigo
em Chinês
| WPRIM
| ID: wpr-247582
ABSTRACT
<p><b>OBJECTIVE</b>To analyze antiviral effects of entecavir in patients with hepatitis B virus-related cirrhosis.</p><p><b>METHODS</b>104 patients of hepatitis B virus-related cirrhosis with no previous history of antiviral therapy were treated with entecavir 0.5 mg once daily. 37 patients were taken hepatic histologic examination before and after the treatment.</p><p><b>RESULTS</b>Mean reductions of serum HBV DNA was 5.1 log10 96 weeks after the treatment, HBV DNA became undetectable in 98.1% patients, and ALT became normal in 80.7% patients; HBeAg seroconversion occurred in 13.9% of the 72 HBeAg positive patients; 61.5% of these patients were infected with genotype C HBV, and 26.9% were infected with genotype B HBV. The genotype of HBV was not associated with the therapeutical effect. Child-pugh score was associated with the progression of the disease the proportion of patients with disease progression was highest in Child-Pugh C grade patients and lowest in Child-Pugh A grade patients. The level of the HBV DNA load was positively correlated with Knodell HAI score at the baseline and 96 weeks after the treatment.</p><p><b>CONCLUSION</b>Entecavir treatment results in suppression of HBV replication and delayed progression of fibrosis in patients with hepatitis B virus-related cirrhosis.</p>
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Assunto principal:
Antivirais
/
Fatores de Tempo
/
Virologia
/
Replicação Viral
/
Sangue
/
DNA Viral
/
Vírus da Hepatite B
/
Resultado do Tratamento
/
Hepatite B Crônica
/
Usos Terapêuticos
Limite:
Adulto
/
Feminino
/
Humanos
/
Masculino
Idioma:
Chinês
Revista:
Chinese Journal of Hepatology
Ano de publicação:
2010
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS